Endothelial Protection, AT1 blockade and Cholesterol-Dependent Oxidative Stress: the EPAS trial
- PMID: 16820589
- DOI: 10.1161/CIRCULATIONAHA.105.001313
Endothelial Protection, AT1 blockade and Cholesterol-Dependent Oxidative Stress: the EPAS trial
Abstract
Background: Statins and angiotensin type 1 (AT1) receptor blockers reduce cardiovascular mortality and morbidity. In the Endothelial Protection, AT1 blockade and Cholesterol-Dependent Oxidative Stress (EPAS) trial, impact of independent or combined statin and AT1 receptor blocker therapy on endothelial expression of anti-atherosclerotic and proatherosclerotic genes and endothelial function in arteries of patients with coronary artery disease were tested.
Methods and results: Sixty patients with stable coronary artery disease undergoing elective coronary artery bypass grafting (CABG) surgery were randomized 4 weeks before surgery to: (A) control without inhibition of renin-angiotensin system or statin; (B) statin (pravastatin 40 mg/d); (C) AT1 blockade (irbesartan 150 mg/d); or (D) combination of statin and AT1 blocker in same dosages. Primary end point was a priori therapy-dependent regulation of an anti-atherosclerotic endothelial expression quotient Q including mRNA expression (in arbitrary units measured by real-time polymerase chain reaction) of endothelial nitric oxide synthase and C-type natriuretic peptide, divided by expression of oxidized low-density lipoprotein receptor LOX-1 and NAD(P)H oxidase subunit gp91phox in left internal mammary arteries biopsies obtained by CABG surgery; 49 patients completed the study. Statin therapy increased lnQ from 3.2+/-0.4 to 4.4+/-0.4 significantly versus control. AT(1) blockade showed a trend to increase lnQ to 4.2+/-0.5. Combination of statin and AT1 blocker further increased lnQ to 5.1+/-0.6, but a putative interaction of both therapies in lnQ was not significant. Furthermore, preoperative therapy with statin, AT1 blocker and their combination improved endothelial function in internal mammary artery rings.
Conclusions: Statin and AT1 blocker therapy independently and in combination improve an anti-atherosclerotic endothelial expression quotient and endothelial function.
Similar articles
-
Dose-dependent regulation of NAD(P)H oxidase expression by angiotensin II in human endothelial cells: protective effect of angiotensin II type 1 receptor blockade in patients with coronary artery disease.Arterioscler Thromb Vasc Biol. 2002 Nov 1;22(11):1845-51. doi: 10.1161/01.atv.0000035392.38687.65. Arterioscler Thromb Vasc Biol. 2002. PMID: 12426214
-
Angiotensin II type 1-receptor antagonism prevents type IIA secretory phospholipase A2-dependent lipid peroxidation.Atherosclerosis. 2007 Sep;194(1):62-70. doi: 10.1016/j.atherosclerosis.2006.09.024. Epub 2006 Oct 27. Atherosclerosis. 2007. PMID: 17069818 Clinical Trial.
-
Impact of a combined treatment of angiotensin II type 1 receptor blockade and 3-hydroxy-3-methyl-glutaryl-CoA-reductase inhibition on secretory phospholipase A2-type IIA and low density lipoprotein oxidation in patients with coronary artery disease.Eur Heart J. 2008 Aug;29(16):1956-65. doi: 10.1093/eurheartj/ehn276. Epub 2008 Jun 18. Eur Heart J. 2008. PMID: 18565968 Clinical Trial.
-
Should angiotensin II receptor blockers and statins be combined?Circulation. 2004 Aug 24;110(8):1013-20. doi: 10.1161/01.CIR.0000139857.85424.45. Circulation. 2004. PMID: 15326080 Review. No abstract available.
-
Angiotensin AT1 receptor over-expression in hypercholesterolaemia.Ann Med. 2000 Sep;32(6):386-9. doi: 10.3109/07853890008995944. Ann Med. 2000. PMID: 11028685 Review.
Cited by
-
Effect of losartan on Doppler sonography indices in kidney transplant patients: a randomized clinical trial.Vasc Health Risk Manag. 2009;5(1):97-100. Epub 2009 Apr 8. Vasc Health Risk Manag. 2009. PMID: 19436681 Free PMC article. Clinical Trial.
-
HMG CoA reductase inhibitors (statins) for preventing acute kidney injury after surgical procedures requiring cardiac bypass.Cochrane Database Syst Rev. 2015 Mar 11;2015(3):CD010480. doi: 10.1002/14651858.CD010480.pub2. Cochrane Database Syst Rev. 2015. PMID: 25758322 Free PMC article.
-
Cardiovascular diseases, lipid-lowering therapies and European registries in the COVID-19 pandemic.Cardiovasc Res. 2020 Aug 1;116(10):e122-e125. doi: 10.1093/cvr/cvaa176. Cardiovasc Res. 2020. PMID: 32678443 Free PMC article. Review. No abstract available.
-
Therapeutic interventions and oxidative stress in diabetes.Front Biosci (Landmark Ed). 2009 Jan 1;14(1):192-209. doi: 10.2741/3240. Front Biosci (Landmark Ed). 2009. PMID: 19273063 Free PMC article. Review.
-
Chronic alcohol intake-induced oxidative stress and apoptosis: role of CYP2E1 and calpain-1 in alcoholic cardiomyopathy.Mol Cell Biochem. 2012 Jan;359(1-2):283-92. doi: 10.1007/s11010-011-1022-z. Epub 2011 Aug 11. Mol Cell Biochem. 2012. PMID: 21833537
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous